Go to content
UR Home

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

Michel, Christian ; Burchert, Andreas ; Hochhaus, Andreas ; Saussele, Susanne ; Neubauer, Andreas ; Lauseker, Michael ; Krause, Stefan W. ; Kolb, Hans-Jochem ; Hossfeld, Dieter Kurt ; Nerl, Christoph ; Baerlocher, Gabriela M. ; Heim, Dominik ; Brümmendorf, Tim H. ; Fabarius, Alice ; Haferlach, Claudia ; Schlegelberger, Brigitte ; Balleisen, Leopold ; Goebeler, Maria-Elisabeth ; Hänel, Mathias ; Ho, Anthony ; Dengler, Jolanta ; Falge, Christiane ; Möhle, Robert ; Kremers, Stephan ; Kneba, Michael ; Stegelmann, Frank ; Köhne, Claus-Henning ; Lindemann, Hans-Walter ; Waller, Cornelius F. ; Spiekermann, Karsten ; Berdel, Wolfgang E. ; Müller, Lothar ; Edinger, Matthias ; Mayer, Jiri ; Beelen, Dietrich W. ; Bentz, Martin ; Link, Hartmut ; Hertenstein, Bernd ; Fuchs, Roland ; Wernli, Martin ; Schlegel, Frank ; Schlag, Rudolf ; de Wit, Maike ; Trümper, Lorenz ; Hebart, Holger ; Hahn, Markus ; Thomalla, Jörg ; Scheid, Christof ; Schafhausen, Philippe ; Verbeek, Walter ; Eckart, Michael J. ; Gassmann, Winfried ; Schenk, Michael ; Brossart, Peter ; Wündisch, Thomas ; Geer, Thomas ; Bildat, Stephan ; Schäfer, Erhardt ; Hasford, Joerg ; Hehlmann, Rüdiger ; Pfirrmann, Markus



Abstract

Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800 mg ('high-dose') imatinib accelerated achievement of a deep molecular remission. However, whether and when a de-escalation of the dose intensity under high-dose imatinib can be safely performed without increasing ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons